Befuraline, a new antidepressant drug, was studied in twenty-nine inpatients with unipolar endogenous depression. The evaluation of patients' condition was made on four different study periods by two assessors using the HDRS, the Beck depression inventory and von Zerssen depression scale. Befuraline, given in oral doses of between 100 and 300 mg/day improved the HDRS total score and the cognitive disturbances to a significant extent (p less than 0.01) after the first week of the treatment. Eleven patients withdrew from the study most of them as a result of intolerance to the stimulatory properties of the drug, however, the response was considered satisfactory in 12 of the 29 patients (41%) mostly in the "retarded depressed" class. As Befuraline proved to be well tolerated, it was continued on an outpatient basis in 11 patients, confirming the absence of clinically important untoward effects.

中文翻译：

---

Befuraline，它在抑郁症住院患者中的安全性和有效性

Befuraline 是一种新的抗抑郁药，在 29 名单相内源性抑郁症住院患者中进行了研究。由两名评估员使用 HDRS、Beck 抑郁量表和 von Zerssen 抑郁量表在四个不同的研究期间对患者的病情进行评估。在治疗的第一周后，以 100 至 300 毫克/天的口服剂量给予贝弗拉林显着改善 HDRS 总分和认知障碍（p 小于 0.01）。11 名患者退出研究，其中大部分是由于对药物的刺激特性不耐受，然而，29 名患者中有 12 名 (41%) 的反应被认为是令人满意的，大多数患者属于“迟缓抑郁”类别。由于 Befuraline 被证明具有良好的耐受性，因此在 11 名患者的门诊基础上继续使用，